

OKLAHOMA BOARD OF NURSING
2501 N. Lincoln Boulevard, Suite 207
Oklahoma City, Oklahoma 73105

**CRNA Formulary Advisory Council
Minutes-April 10, 2023**

The CRNA Formulary Advisory Council (“Council”) to the Oklahoma Board of Nursing (“Board”) met on April 10, 2023. Notice of the meeting was initially filed with the Secretary of State’s Office on December 8, 2022, and amended on February 13, 2023. Notice of the meeting was posted on the Oklahoma Board of Nursing web site not less than 24 hours prior to the meeting. A notice/agenda was also posted on the Connors Building front entrance at 2501 North Lincoln Boulevard, Oklahoma City, Oklahoma, as well as the Board office at 2501 N. Lincoln Boulevard, Suite 207, not less than 24 hours prior to the meeting.

Place of Meeting: ARC Conference Room, Suite 400, Connors Building

Time of Meeting: 3:30 PM

Members Present: Mark St Cyr, D.Ph.
Oklahoma Pharmacists Association

Jeremy Almon, MD
Oklahoma Society of Anesthesiologists

Jenny Schmitt, APRN-CRNA (arrived 4:02 PM)
Oklahoma Association of Nurse Anesthetists

Bruce Kennedy, APRN-CRNA
Oklahoma Association of Nurse Anesthetists

Members Absent: Brian Seacat, MD
Oklahoma Society of Anesthesiologists

Board Representative: Amber Garrettson, APRN-CNS, CCRN

Staff Representatives: Madison Edwards, MS, RN
Jackye Ward, MSN, RN, FRE
Michael Starchman, RN, CPA

Guest: None

1.0 Call to order: The meeting was called to order at 3:41 PM by M. St Cyr, Chairperson.

1.1 Declaration of a quorum: A quorum was declared present.

1.2 Reminder of voting members: 1 doctor, 1 pharmacist, and 1 CRNA present

- 2.0 Minutes of the previous meeting – April 25, 2022:** The minutes were reviewed. A motion was made (B. Kennedy) and seconded to approve the minutes of April 25, 2022, with the corrections.

Voting:

Yes: (3) B. Kennedy, M. St Cyr, J. Almon
No: (0)
Absent: (2) J. Schmitt, B. Seacat

Motion Carried.

3.0 Board Update (verbal reports only, requiring no action by Committee):

- 3.1 Proposed Permanent Rules:** J. Ward summarized proposed changes to the *Oklahoma Board of Nursing Rules*. Subchapter 5 – new language recognizing the privilege to practice in OK off of a MSL from another compact party state; Subchapter 7 – adding another option for foreign credential evaluation for applicants educated in another country and adding another option for English language test for competence in oral and written English; Subchapter 11: new language clarifying the 20-day timeline of sending written orders to licensees and applicants following review of Board Orders by the Attorney General’s office; amended language regarding Board orders following disciplinary action, felony convictions as they relate to the licensure of individuals with a criminal history, and Subchapter 18 – Certified Registered Nurse Anesthetist (CRNA) initial application criteria clarifying the options of meeting the pharmacology requirements for CRNA renewal.
- 3.2 Approved Emergency Rules, Subchapter 23:** J. Ward summarized the proposed emergency rule revisions in OAC 485:10-5-4.1 which provides an option for Board-approved nursing education programs with at least 600 total program clinical hours to provide 50% simulated patient care experiences, provided at least one instructor in the nursing education program be simulation certified. The emergency rules were approved by Governor Stitt on March 10, 2023. The expiration date of the approved emergency rules is September 14, 2024.
- 3.3 No business**
- 3.4 CRNA Reminder Specific to Legend Drugs:** J. Ward provided updates regarding SB0458, HB1005, HB1709, HB1650, SB0132, SB0613, and SB0665.
- 3.5 Prescribing changes for Buprenorphine:** M. Edwards provided an update regarding DEA changes to requirements for prescribing Buprenorphine. DEA DATA waiver and X DEA numbers are no longer required for prescribers. There is no longer a limit on the number of patients a prescriber can treat with Buprenorphine. New training will be required with the effective date June 27, 2023. The DEA will provide information regarding the education at a later date.

3.5 CRNA Formulary Advisory Council membership: M. Edwards reported J. Almon to expire or reappoint September 2023. Following his retirement, M. St. Cyr will await a replacement appointee from the Oklahoma Pharmacists Association.

3.6 Other: J. Ward introduced M. Starchman as new Deputy Executive Director for the agency and will begin orientation to the new position in June 2023.

4.0 Review and committee recommendation on CRNA Inclusionary Formulary: M. Edwards noted a review of the American Hospital Formulary Service Drug Information was conducted with a focus on drug assignments and reassignments made since the previous annual meeting, April, 25, 2022. No updates or revisions were made. Council members reviewed the DRAFT *CRNA Inclusionary Formulary*, #P-50A. It was moved (J. Schmitt) and seconded to move forward with Board approval:

Voting:

Yes: (4) B. Kennedy, M. St Cyr, J. Almon, J. Schmitt
No: (0)
Absent: (1) B. Seacat

Motion Carried.

5.0 Election of Chairperson for 2024: It was moved (J. Schmitt) and seconded to appoint Bruce Kennedy as Chairperson for the next CRNA Formulary Advisory Council Meeting.

Voting:

Yes: (4) B. Kennedy, M. St Cyr, J. Almon, J. Schmitt
No: (0)
Absent: (1) B. Seacat

Motion Carried.

Election of Vice Chairperson for 2024: It was moved (J. Schmitt) and seconded to appoint Brian Seacat as Vice Chairperson for the next CRNA Formulary Advisory Council Meeting.

Voting:

Yes: (4) B. Kennedy, M. St Cyr, J. Almon, J. Schmitt
No: (0)
Absent: (1) B. Seacat

Motion Carried.

6.0 Date for next meeting: The members discussed possible dates and times for the next meeting.

6.1 A motion was made (B. Kennedy) and seconded for the next meeting to occur Monday, April 22, 2024, at 3:30 PM.

Voting:

Yes: (4) B. Kennedy, M. St Cyr, J. Almon, J. Schmitt

No: (0)

Absent: (1) B. Seacat

Motion Carried.

7.0 Adjournment: There being no further business, it was moved (B. Kennedy) and seconded to adjourn. The meeting was adjourned at 4:18 PM.

Voting:

Yes: (4) B. Kennedy, M. St Cyr, J. Almon, J. Schmitt

No: (0)

Absent: (1) B. Seacat

Motion Carried.